Selected research
Industry Research
Chemical API CDMO Industry Research Report 2026
Market perspective
The global Chemical API CDMO market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Chemical API CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Chemical API CDMO market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Chemical API CDMO market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Chemical API CDMO include Flamma Group, HAS Healthcare, Asymchem, Recipharm, Pierre Fabre, Pfizer CentreOne, Axplora, Lonza and MAI CDMO, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Chemical API CDMO market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Chemical API CDMO.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Chemical API CDMO Market by Company
Flamma Group
HAS Healthcare
Asymchem
Recipharm
Pierre Fabre
Pfizer CentreOne
Axplora
Lonza
MAI CDMO
BioVectra
Curia
AGC Pharma Chemicals
Asymchem
Olon Group
Evonik Health Care
Teva Active Pharmaceutical Ingredients
Chemical API CDMO Segment by Type
Small Molecule CDMO
Macromolecule CDMO
Cell Gene Therapy (CGT) CDMO
Chemical API CDMO Segment by Application
Pharmaceutical and Biotechnology Companies
Research and Academic Institutions
Hospital
Others
Chemical API CDMO Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chemical API CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Chemical API CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chemical API CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Chemical API CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Small Molecule CDMO
- Macromolecule CDMO
- Cell Gene Therapy (CGT) CDMO
Applications
- Pharmaceutical and Biotechnology Companies
- Research and Academic Institutions
- Hospital
- Others
Companies covered
- Flamma Group
- HAS Healthcare
- Asymchem
- Recipharm
- Pierre Fabre
- Pfizer CentreOne
- Axplora
- Lonza
- MAI CDMO
- BioVectra
- Curia
- AGC Pharma Chemicals
- Asymchem
- Olon Group
- Evonik Health Care
- Teva Active Pharmaceutical Ingredients
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Chemical API CDMO by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Small Molecule CDMO
- 2.2.3 Macromolecule CDMO
- 2.2.4 Cell Gene Therapy (CGT) CDMO
- 2.3 Chemical API CDMO by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Pharmaceutical and Biotechnology Companies
- 2.3.3 Research and Academic Institutions
- 2.3.4 Hospital
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Chemical API CDMO Breakdown Data by Type
- 3.1 Global Chemical API CDMO Historic Market Size by Type (2021-2026)
- 3.2 Global Chemical API CDMO Forecasted Market Size by Type (2027-2032)
4 Chemical API CDMO Breakdown Data by Application
- 4.1 Global Chemical API CDMO Historic Market Size by Application (2021-2026)
- 4.2 Global Chemical API CDMO Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Chemical API CDMO Market Perspective (2021-2032)
- 5.2 Global Chemical API CDMO Growth Trends by Region
- 5.2.1 Global Chemical API CDMO Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Chemical API CDMO Historic Market Size by Region (2021-2026)
- 5.2.3 Chemical API CDMO Forecasted Market Size by Region (2027-2032)
- 5.3 Chemical API CDMO Market Dynamics
- 5.3.1 Chemical API CDMO Industry Trends
- 5.3.2 Chemical API CDMO Market Drivers
- 5.3.3 Chemical API CDMO Market Challenges
- 5.3.4 Chemical API CDMO Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Chemical API CDMO Players by Revenue
- 6.1.1 Global Top Chemical API CDMO Players by Revenue (2021-2026)
- 6.1.2 Global Chemical API CDMO Revenue Market Share by Players (2021-2026)
- 6.2 Global Chemical API CDMO Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Chemical API CDMO Head Office and Area Served
- 6.4 Global Chemical API CDMO Players, Product Type & Application
- 6.5 Global Chemical API CDMO Manufacturers Established Date
- 6.6 Global Chemical API CDMO Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Chemical API CDMO Market Size (2021-2032)
- 7.2 North America Chemical API CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Chemical API CDMO Market Size by Country (2021-2026)
- 7.4 North America Chemical API CDMO Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Chemical API CDMO Market Size (2021-2032)
- 8.2 Europe Chemical API CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Chemical API CDMO Market Size by Country (2021-2026)
- 8.4 Europe Chemical API CDMO Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Chemical API CDMO Market Size (2021-2032)
- 9.2 Asia-Pacific Chemical API CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Chemical API CDMO Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Chemical API CDMO Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Chemical API CDMO Market Size (2021-2032)
- 10.2 South America Chemical API CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Chemical API CDMO Market Size by Country (2021-2026)
- 10.4 South America Chemical API CDMO Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Chemical API CDMO Market Size (2021-2032)
- 11.2 Middle East & Africa Chemical API CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Chemical API CDMO Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Chemical API CDMO Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Flamma Group
- 12.1.1 Flamma Group Company Information
- 12.1.2 Flamma Group Business Overview
- 12.1.3 Flamma Group Revenue in Chemical API CDMO Business (2021-2026)
- 12.1.4 Flamma Group Chemical API CDMO Product Portfolio
- 12.1.5 Flamma Group Recent Developments
- 12.2 HAS Healthcare
- 12.2.1 HAS Healthcare Company Information
- 12.2.2 HAS Healthcare Business Overview
- 12.2.3 HAS Healthcare Revenue in Chemical API CDMO Business (2021-2026)
- 12.2.4 HAS Healthcare Chemical API CDMO Product Portfolio
- 12.2.5 HAS Healthcare Recent Developments
- 12.3 Asymchem
- 12.3.1 Asymchem Company Information
- 12.3.2 Asymchem Business Overview
- 12.3.3 Asymchem Revenue in Chemical API CDMO Business (2021-2026)
- 12.3.4 Asymchem Chemical API CDMO Product Portfolio
- 12.3.5 Asymchem Recent Developments
- 12.4 Recipharm
- 12.4.1 Recipharm Company Information
- 12.4.2 Recipharm Business Overview
- 12.4.3 Recipharm Revenue in Chemical API CDMO Business (2021-2026)
- 12.4.4 Recipharm Chemical API CDMO Product Portfolio
- 12.4.5 Recipharm Recent Developments
- 12.5 Pierre Fabre
- 12.5.1 Pierre Fabre Company Information
- 12.5.2 Pierre Fabre Business Overview
- 12.5.3 Pierre Fabre Revenue in Chemical API CDMO Business (2021-2026)
- 12.5.4 Pierre Fabre Chemical API CDMO Product Portfolio
- 12.5.5 Pierre Fabre Recent Developments
- 12.6 Pfizer CentreOne
- 12.6.1 Pfizer CentreOne Company Information
- 12.6.2 Pfizer CentreOne Business Overview
- 12.6.3 Pfizer CentreOne Revenue in Chemical API CDMO Business (2021-2026)
- 12.6.4 Pfizer CentreOne Chemical API CDMO Product Portfolio
- 12.6.5 Pfizer CentreOne Recent Developments
- 12.7 Axplora
- 12.7.1 Axplora Company Information
- 12.7.2 Axplora Business Overview
- 12.7.3 Axplora Revenue in Chemical API CDMO Business (2021-2026)
- 12.7.4 Axplora Chemical API CDMO Product Portfolio
- 12.7.5 Axplora Recent Developments
- 12.8 Lonza
- 12.8.1 Lonza Company Information
- 12.8.2 Lonza Business Overview
- 12.8.3 Lonza Revenue in Chemical API CDMO Business (2021-2026)
- 12.8.4 Lonza Chemical API CDMO Product Portfolio
- 12.8.5 Lonza Recent Developments
- 12.9 MAI CDMO
- 12.9.1 MAI CDMO Company Information
- 12.9.2 MAI CDMO Business Overview
- 12.9.3 MAI CDMO Revenue in Chemical API CDMO Business (2021-2026)
- 12.9.4 MAI CDMO Chemical API CDMO Product Portfolio
- 12.9.5 MAI CDMO Recent Developments
- 12.10 BioVectra
- 12.10.1 BioVectra Company Information
- 12.10.2 BioVectra Business Overview
- 12.10.3 BioVectra Revenue in Chemical API CDMO Business (2021-2026)
- 12.10.4 BioVectra Chemical API CDMO Product Portfolio
- 12.10.5 BioVectra Recent Developments
- 12.11 Curia
- 12.11.1 Curia Company Information
- 12.11.2 Curia Business Overview
- 12.11.3 Curia Revenue in Chemical API CDMO Business (2021-2026)
- 12.11.4 Curia Chemical API CDMO Product Portfolio
- 12.11.5 Curia Recent Developments
- 12.12 AGC Pharma Chemicals
- 12.12.1 AGC Pharma Chemicals Company Information
- 12.12.2 AGC Pharma Chemicals Business Overview
- 12.12.3 AGC Pharma Chemicals Revenue in Chemical API CDMO Business (2021-2026)
- 12.12.4 AGC Pharma Chemicals Chemical API CDMO Product Portfolio
- 12.12.5 AGC Pharma Chemicals Recent Developments
- 12.13 Asymchem
- 12.13.1 Asymchem Company Information
- 12.13.2 Asymchem Business Overview
- 12.13.3 Asymchem Revenue in Chemical API CDMO Business (2021-2026)
- 12.13.4 Asymchem Chemical API CDMO Product Portfolio
- 12.13.5 Asymchem Recent Developments
- 12.14 Olon Group
- 12.14.1 Olon Group Company Information
- 12.14.2 Olon Group Business Overview
- 12.14.3 Olon Group Revenue in Chemical API CDMO Business (2021-2026)
- 12.14.4 Olon Group Chemical API CDMO Product Portfolio
- 12.14.5 Olon Group Recent Developments
- 12.15 Evonik Health Care
- 12.15.1 Evonik Health Care Company Information
- 12.15.2 Evonik Health Care Business Overview
- 12.15.3 Evonik Health Care Revenue in Chemical API CDMO Business (2021-2026)
- 12.15.4 Evonik Health Care Chemical API CDMO Product Portfolio
- 12.15.5 Evonik Health Care Recent Developments
- 12.16 Teva Active Pharmaceutical Ingredients
- 12.16.1 Teva Active Pharmaceutical Ingredients Company Information
- 12.16.2 Teva Active Pharmaceutical Ingredients Business Overview
- 12.16.3 Teva Active Pharmaceutical Ingredients Revenue in Chemical API CDMO Business (2021-2026)
- 12.16.4 Teva Active Pharmaceutical Ingredients Chemical API CDMO Product Portfolio
- 12.16.5 Teva Active Pharmaceutical Ingredients Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst